Jiangsu Hualv Biological Technology Co.Ltd. (300970) — Capital Reinvestment Ratio
Jiangsu Hualv Biological Technology Co.Ltd. (300970) has a Capital Reinvestment Ratio of 0.36x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥345.31 Million) in capital expenditures (CN¥123.12 Million). Check Jiangsu Hualv Biological Technology Co.L (300970) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Jiangsu Hualv Biological Technology Co.Ltd. Capital Reinvestment Ratio (2019–2025)
This chart tracks Jiangsu Hualv Biological Technology Co.Ltd.'s Capital Reinvestment Ratio across 7 annual periods. For the full cash flow conversion analysis, see Jiangsu Hualv Biological Technology Co.L cash flow conversion.
Annual Capital Reinvestment Ratio for Jiangsu Hualv Biological Technology Co.Ltd. (2019–2025)
Year-by-year Capital Reinvestment Ratio for Jiangsu Hualv Biological Technology Co.Ltd. from 2019 to 2025. See 300970 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.36x | CN¥345.31 Million | CN¥123.12 Million | ▼ -81.7% |
| 2024 | 1.95x | CN¥137.80 Million | CN¥268.22 Million | ▲ +44.7% |
| 2023 | 1.34x | CN¥166.67 Million | CN¥224.15 Million | ▼ -40.7% |
| 2022 | 2.27x | CN¥179.84 Million | CN¥407.91 Million | ▼ -7.7% |
| 2021 | 2.46x | CN¥83.08 Million | CN¥204.09 Million | ▲ +156.1% |
| 2020 | 0.96x | CN¥199.09 Million | CN¥190.96 Million | ▲ +108.3% |
| 2019 | 0.46x | CN¥213.96 Million | CN¥98.54 Million | — |